ClinicalTrials.gg
Not yet recruitingNCT06794801Updated Jan 27, 2025

Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study

An interventional study of Drug Coated Autoperfusion Balloon Dilatation Catheter(DCAB) and Conventional Drug coated balloon (DCB) in ST Segment Elevation Myocardial Infarction (STEMI), sponsored by LanZhou University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by LanZhou University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 40 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
79th of 97
134 · median 320
Started
2025
with 10 others
No phase
51 of 146
21 open now
Primary completion
2026-12
later than 13 of 42 live
Registered
121st of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 79th largest by planned enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2025, is one of 51 with no phase, reaches primary completion later than 13 of the 42 other live ones, and was the 121st registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

40 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

Trial Goals:

  1. Evaluation of Mid- to Long-Term Safety and Effectiveness of Drug-Coated Autoperfusion Balloon Dilatation Catheter (DCAB) versus Conventional Drug coated balloon (DCB) in Patients with ST Segment Elevation Myocardial Infarction (STEMI).
  2. Evaluation of Hybrid IVUS-OCT System for Intraoperative Evaluation of DCAB or Conventional DCB Treatment Safety and Effectiveness for De Novo Lesions During Emergency Percutaneous Coronary Intervention (PCI) in Patients with STEMI.

The primary outcome is late lumen loss (LLL) assessed at 9 months following emergency PCI, measured using quantitative coronary angiography (QCA).

03

Conditions studied

  • ST Segment Elevation Myocardial Infarction (STEMI)

Keywords

  • Drug Coated Autoperfusion Balloon Dilatation Catheter
  • Percutaneous Coronary Intervention
  • VUS-OCT Multimodal Imaging
  • De novo lesion
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute ST-Elevation Myocardial Infarction Meeting PPCI Criteria: 1) Chest pain lasting more than 20 minutes, with ST-segment elevation of at least 1 mm in two or more adjacent leads, new left bundle branch block, or evidence of posterior wall myocardial infarction; 2) Onset of symptoms within 12 hours.
  2. Patients Who Have Received Thrombolytic Therapy Within 6 Hours of Symptom Onset and Are Eligible for Rescue PCI Within 24 Hours;
  3. Infarct-Related Artery Selection Imaging and Pre-Treatment Criteria Meeting PPCI Standards: 1) De novo lesions. 2) Reference vessel diameter between 2.5 mm and 4 mm. 3) Successful pre-treatment of target lesions: post-pre-treatment residual stenosis of the culprit vessel ≤ 30%, with no type C dissections (or intravascular imaging indicating significant residual plaque burden at the site of dissection, with transverse expansion > 60°, longitudinal expansion > 2 mm, dissection involving the media or adventitia, and located at the distal end of the stent), no hematoma, and no significant thrombus (TIMI thrombus burden grade ≤ 2);
  4. Sufficient compliance with the study protocol, agreement to undertake follow-up, and coronary angiography at 9 months;
  5. Voluntary Participation in This Study, Including Signing a Written with Understanding of All Risks and Benefits Described in the Informed Consent Document.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years and > 75 years;
  2. History of prior myocardial infarction;
  3. Allergy to contrast agent/inability to tolerate contrast;
  4. Known / inability to tolerate bivalirudin, fondaparinux, heparin, aspirin, clopidogrel, and/or ticagrelor;
  5. Complex coronary lesions: left main lesions, lesions at the ostia of the left anterior descending or circumflex arteries, lesion length > 30 mm, severe calcification, severe tortuosity or angulation, bifurcation lesions requiring the implantation of more than two drug-coated balloons (DCBs) or drug-eluting stents;
  6. In-stent restenosis or in-stent thrombus lesions;
  7. Planned simultaneous intervention on non-target lesions;
  8. Active bleeding or recent history of bleeding;
  9. Uncertain neurological outcomes, such as resuscitation;
  10. Intubation / ventilation;
  11. Cardiogenic shock prior to randomization;
  12. Known intracranial disease (tumors, aneurysms, arteriovenous malformations, hemorrhagic CVA, ischemic CVA/ within the last 6 months, including permanent neurological deficits from ischemic cerebrovascular disease) ;
  13. Refusal of blood transfusion;
  14. Planned major surgery within 6 weeks;
  15. Stent implantation \< 1 month prior to enrollment;
  16. of less than 12 months;
  17. Participation in another clinical trial that interferes with this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Drug Coated Autoperfusion Balloon Dilatation Catheter(DCAB)

    3 μg/mm² paclitaxel-coated drug-coated autoperfusion balloon dilatation catheter (DCAB). The DCAB features two radiopaque marker rings at the balloon shoulders for intravascular imaging and positioning, self-perfusion holes on the catheter shaft, and an additional radiopaque marker ring proximal to the perfusion holes to indicate their location. The catheter shaft is hydrophilically coated to facilitate blood flow through the perfusion holes when the guidewire is retracted. Preclinical studies show this design allows 15%-20% of arterial blood to reach the distal coronary artery.

    Device: Drug Coated Autoperfusion Balloon Dilatation Catheter(DCAB)

  • Active comparator
    Conventional Drug coated ballon(DCB)

    Bingo® PTCA Drug Delivery System: drug (paclitaxel) coated balloon (DCB) with concentration of 3 μg Paclitaxel per 1 mm2.

    Device: Conventional Drug coated balloon (DCB)

Interventions

  • DeviceDrug Coated Autoperfusion Balloon Dilatation Catheter(DCAB)

    In the experimental arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successfully prepared lesions will be treated with a drug-coated autoperfusion balloon dilatation catheter (DCAB). Successful lesion preparation is defined as post-pretreatment residual stenosis ≤ 30%, no type C dissections, intravascular imaging confirming no significant residual plaque burden at the dissection site, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no dissection involving the media or adventitia, and no location at the stent distal end. There should be no hematoma and no significant thrombus (TIMI thrombus burden grade ≤ 2). If the angiographic and intravascular imaging results after DCAB treatment are unsatisfactory, an emergency drug-eluting stent (DES) will be implanted.

  • DeviceConventional Drug coated balloon (DCB)

    In the control arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successful lesion preparation (residual stenosis ≤ 30%, no type C dissections, no significant residual plaque burden, no dissection involving the media or adventitia, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no location at the stent distal end, no hematoma, TIMI thrombus burden grade ≤ 2) will be treated with a conventional DCB coated with 3 μg/mm2 paclitaxel. If angiographic and intravascular imaging results are unsatisfactory, a bailout DES will be implanted.

    Also known as: Bingo® PTCA Drug Delivery System

06

What researchers measure

Primary outcomes

  1. Late lumen loss at 9 months after index PCI

    Late lumen loss, as assessed by quantitative coronary angiography, at 9 months following the index percutaneous coronary intervention.

    Time frame: 9±2 months

Secondary outcomes

  1. Incidence of patient-oriented composite endpoint (PoCE)

    Incidence of patient-oriented composite endpoint (PoCE) and individual components of PoCE: defined as a composite of all-cause death, Target vessel failure, any stroke, any myocardial infarction (MI), and any clinically or physiologically indicated revascularization.

    Time frame: 3±1 Months, 6±1 Months, 9±2 Months, 2 Years, 3 Years, 4 Years, and 5 Years after PCI

  2. Incidence of Bleeding Academic Research Consortium bleeding type 3 and 5 bleeding complications

    Bleeding Academic Research Consortium type 3 and 5 bleeding complications

    Time frame: 3±1 Months, 6±1 Months, 9±2 Months, 2 Years, 3 Years, 4 Years, and 5 Years after PCI

  3. Incidence of coronary dissection, categorized by Types A, B, C, and D-F, immediately following DCB implantation

    Based on the results of coronary angiography after DCB implantation

    Time frame: index PCI

  4. The incidence of bailout stenting following DCB implantation

    The following criteria are used to define it: TIMI flow ≤ Grade 2; residual stenosis \> 30%; Type C (or intravascular imaging demonstrating significant residual plaque burden at the dissection site, lateral extension \> 60°, longitudinal extension \> 2 mm, dissection involving the media or adventitia); and higher dissection.

    Time frame: index PCI

  5. Minimum lumen area and Lumen Area Loss Immediately After DCB Implantation by IVUS-OCT Intravascular Imaging.

    Change in minimum lumen area and lumen area loss (in mm2), as assessed by IVUS-OCT multimodal imaging, compared with pre-procedure baseline following coronary artery drug-coated balloon angioplasty.

    Time frame: index PCI

  6. Incidence of intolerable adverse events during the duration of coronary artery drug-coated balloon dilation.

    Incidence of intolerable worsening chest pain, hemodynamic instability, ST-segment changes, and severe arrhythmias during DCB expansion and duration of DCB expansion.

    Time frame: index PCI

07

Study locations

1 site
  • LanZhou University
    Lanzhou, Gansu 730000, China
    • Jing Zhao, Dr · Contactjzhao14@fudan.edu.cn · +8618919062327
    • Yurun Su · Contact15682845605@163.com · +8615682845605
    • Yurun Su, M.S. · Sub investigator
    • Jing Zhao, M.D. · Sub investigator
    • Bo Zhang, B.S. · Sub investigator
    • Youqi Zhu, B.S. · Sub investigator
    • Xinghu Zhou, M.D. · Sub investigator
    • Cunrui Zhao, M.S. · Sub investigator
    • Peng Lei, M.D. · Sub investigator
    • Erkun Xing, B.S. · Sub investigator
    • Jinglei Niu, M.S. · Sub investigator
    • Junqian Wang, M.S. · Sub investigator
    • Wei Hu, M.S. · Sub investigator
    • Zhijie Yan, M.S. · Sub investigator
    • Xuan Qiao, M.S. · Sub investigator
08

References and documents

Publications

  • Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 Jan 4;361(9351):13-20. doi: 10.1016/S0140-6736(03)12113-7. PubMed 12517460 ↗
  • Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999 Dec 23;341(26):1949-56. doi: 10.1056/NEJM199912233412601. PubMed 10607811 ↗
  • Suryapranata H, van 't Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 1998 Jun 30;97(25):2502-5. doi: 10.1161/01.cir.97.25.2502. PubMed 9657469 ↗
  • Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC; RAVEL Study Group. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002 Aug 13;106(7):798-803. doi: 10.1161/01.cir.0000025585.63486.59. PubMed 12176950 ↗
  • McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004 Oct 23-29;364(9444):1519-21. doi: 10.1016/S0140-6736(04)17275-9. PubMed 15500897 ↗
  • Brott BC, Anayiotos AS, Chapman GD, Anderson PG, Hillegass WB. Severe, diffuse coronary artery spasm after drug-eluting stent placement. J Invasive Cardiol. 2006 Dec;18(12):584-92. PubMed 17197707 ↗
  • Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008 Sep 9;118(11):1138-45. doi: 10.1161/CIRCULATIONAHA.107.762047. Epub 2008 Aug 25. PubMed 18725485 ↗
  • Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv. 2011 Jan;4(1):24-9. doi: 10.1016/j.jcin.2010.11.003. PubMed 21251625 ↗
  • Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv. 2009 May;2(5):445-52. doi: 10.1016/j.jcin.2009.01.012. PubMed 19463469 ↗
  • Ali RM, Abdul Kader MASK, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, Mahmood Zuhdi AS, Nuruddin AA, Schnorr B, Scheller B. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. JACC Cardiovasc Interv. 2019 Mar 25;12(6):558-566. doi: 10.1016/j.jcin.2018.11.040. PubMed 30898253 ↗
  • Jeger RV, Farah A, Ohlow MA, Mangner N, Mobius-Winkler S, Weilenmann D, Wohrle J, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020 Nov 7;396(10261):1504-1510. doi: 10.1016/S0140-6736(20)32173-5. Epub 2020 Oct 19. Erratum In: Lancet. 2020 Nov 7;396(10261):1490. doi: 10.1016/S0140-6736(20)32283-2. PubMed 33091360 ↗
  • Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX; International DCB Consensus Group. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402. doi: 10.1016/j.jcin.2020.02.043. Epub 2020 May 27. PubMed 32473887 ↗
  • Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman JP, Kiemeneij F, Patterson MS, Slagboom T, van der Schaaf RJ. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention. 2014 Sep;10(5):584-90. doi: 10.4244/EIJV10I5A101. PubMed 25256200 ↗
  • Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006 Sep 14;355(11):1105-13. doi: 10.1056/NEJMoa062598. PubMed 16971717 ↗
  • Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007 Nov;28(22):2706-13. doi: 10.1093/eurheartj/ehm402. Epub 2007 Sep 27. PubMed 17901079 ↗
  • Kim HS, Lee JH, Lee SW, Kim YH, Park JH, Choi SW, Jeong JO, Seong IW, Rhee KS, Ko JK, Jo SH, Choi YJ. Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol. 2011 Mar 3;147(2):253-7. doi: 10.1016/j.ijcard.2009.09.466. Epub 2009 Sep 26. PubMed 19783056 ↗
  • Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, Vink MA. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1691-1699. doi: 10.1016/j.jcin.2019.04.016. Epub 2019 May 21. PubMed 31126887 ↗
  • Gao C, He X, Ouyang F, Zhang Z, Shen G, Wu M, Yang P, Ma L, Yang F, Ji Z, Wang H, Wu Y, Fang Z, Jiang H, Wen S, Liu Y, Li F, Zhou J, Zhu B, Liu Y, Zhang R, Zhang T, Wang P, Liu J, Jiang Z, Xia J, van Geuns RJ, Capodanno D, Garg S, Onuma Y, Wang D, Serruys PW, Tao L; REC-CAGEFREE I Investigators. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial. Lancet. 2024 Sep 14;404(10457):1040-1050. doi: 10.1016/S0140-6736(24)01594-0. Epub 2024 Sep 2. PubMed 39236727 ↗
  • Hao X, Huang D, Wang Z, Zhang J, Liu H, Lu Y. Correction to: Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. J Cardiothorac Surg. 2021 Sep 3;16(1):247. doi: 10.1186/s13019-021-01629-1. No abstract available. PubMed 34474673 ↗

Individual participant data

Plan to share: Yes — The data is available and can be requested, subject to approval, if a reasonable clinical research analysis plan is provided to the corresponding author.

Supporting information: Clinical study report

Time frame: 6 months

Access criteria: Submit a detailed research analysis plan to the corresponding author and apply through our email.

Data sharing details ↗ · www.lzdxdyyy.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 23 months is below that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 27, 2025
StartEst.
Jan 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2030
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06794801
Lead sponsor
LanZhou University
Responsible party
BAI MING (MD, LanZhou University) — Principal investigator
First posted
Jan 27, 2025
Start date
Jan 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jan 27, 2025

Study contacts

Jing Zhao, Dr
Contact
jzhao14@fudan.edu.cn
+8618919062327
Yurun Su, Dr
Contact
15682845605@163.com
+8615682845605

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion